Head-To-Head Review: OrganiGram (OGI) & Its Rivals

OrganiGram (NASDAQ: OGI) is one of 597 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its peers? We will compare OrganiGram to related companies based on the strength of its profitability, earnings, analyst recommendations, risk, dividends, valuation and institutional ownership.

Institutional & Insider Ownership

11.8% of OrganiGram shares are held by institutional investors. Comparatively, 45.9% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 15.9% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares OrganiGram and its peers revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
OrganiGram $61.27 million -$7.20 million 42.33
OrganiGram Competitors $2.10 billion $222.94 million -3.96

OrganiGram’s peers have higher revenue and earnings than OrganiGram. OrganiGram is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares OrganiGram and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
OrganiGram -11.16% -7.21% -5.28%
OrganiGram Competitors -2,493.25% -850.54% -32.09%

Analyst Ratings

This is a summary of recent ratings for OrganiGram and its peers, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OrganiGram 0 4 5 0 2.56
OrganiGram Competitors 5838 15913 31700 1226 2.52

OrganiGram currently has a consensus price target of $10.96, indicating a potential upside of 331.50%. As a group, “Pharmaceutical preparations” companies have a potential upside of 43.03%. Given OrganiGram’s stronger consensus rating and higher probable upside, equities research analysts clearly believe OrganiGram is more favorable than its peers.

About OrganiGram

OrganiGram Holdings Inc., through its subsidiaries, produces and sells dried cannabis and cannabis oil in Canada. It also offers wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis oils to retailers and wholesalers. The company also exports its products. It sells its products online, as well as through phone orders. OrganiGram Holdings Inc. was founded in 2013 and is headquartered in Moncton, Canada.

Receive News & Ratings for OrganiGram Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrganiGram and related companies with MarketBeat.com's FREE daily email newsletter.